Sponsors / JSPR
JSPR

Jasper Therapeutics, Inc.

Company identity checked against sources

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
1Trials in this database
7Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria TrialsNCT06736262JSPRPhase 2Terminated2026-07-21Actual

Latest recorded trial changes

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

NCT06736262 · Jasper Therapeutics, Inc.

· 4 fields changed

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

90 participants (planned)

+ After

67 participants (actual)

Primary completion date changed

− Before

1 Dec 2026

+ After

13 Aug 2026

Recruitment status changed

− Before

Enrolling by invitation

+ After

Active not recruiting

Check registry source